12th July 2021 Product update: bioMérieux (Clinical Diagnostics)
bioMérieux to Distribute Specific Diagnostics’ REVEAL Rapid AST System in Europe
Developed by Specific Diagnostics, and based on its unique, patented metabolomic signature technology, the REVEAL Rapid AST system provides actionable results for bloodstream infections (in an average of 5 hours* directly from positive blood culture), allowing either timely de-escalation to a focused, more appropriate and lower-cost therapy, or life-saving rapid escalation to a more effective drug where a multidrug-resistant (MDR) infection is present.
REVEAL Rapid AST offers customers an easy to use instrument with a targeted menu, small footprint, and modular design well-suited for a large number of hospitals.
REVEAL Rapid AST system is a perfect complement to bioMérieux’s unique suite of systems delivering rapid results including the industry’s fastest blood culture system, the BACT/ALERT® VIRTUO®, and rapid identification with either VITEK® MS PRIME or BIOFIRE® BCID2, and VITEK® 2. Adding REVEAL Rapid AST enables hospitals to have the fastest possible path to fully actionable results, combining ID (microbial identification) and AST, to allow clinicians to diagnose and treat patients much faster, establishing a new standard of care.Pierre Boulud, Chief Operating Officer, Clinical Operations, bioMérieux declared: "With the addition of Specific Diagnostics’ REVEAL Rapid AST system into its microbiology offer, bioMérieux demonstrates its commitment to provide fast AST to clinicians and laboratories, with the double objective of dramatically improving patient outcomes and serving antimicrobial stewardship, leveraging our extensive distribution network.”
* Tibbetts et al, ECCMID 2020 and in review.
Date Published: 12th July 2021
Source article link: View
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
PREvalence ddPCR SARS-CoV-2 Wastewater Quantification
ScanStation® 2021 New Features